Therapeutic options and challenges for substances of abuse

Dialogues in Clinical Neuroscience

Volumn 9, Issue 4, 2007, Pages 431-445

  Gardner, Tracie J ^a,b   Kosten, Thomas R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Addictive disorders; Substance abuse

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BACLOFEN; BUPRENORPHINE PLUS NALOXONE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; CLONIDINE; COCAINE; DESIPRAMINE; DIAZEPAM; DISULFIRAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LORAZEPAM; METHADONE; NALTREXONE; NICOTINE; NICOTINE VACCINE; NORTRIPTYLINE; OXAZEPAM; PLACEBO; SELEGILINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VARENICLINE;

ALCOHOLISM; BEHAVIOR THERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; ORTHOSTATIC HYPOTENSION; PSYCHOPHARMACOTHERAPY; RASH; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SKIN IRRITATION; SUBSTANCE ABUSE; VIVID DREAM; XEROSTOMIA;

ANIMALS; DRUG THERAPY; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 38549095508     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Centers for Disease Control and Prevention. Tobacco use among adults - United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1145-1148.
2. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHA Publication No. SMA 06-4194). Rockville, MD; 2006.
3. Centers for Disease Control and Prevention. Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Economic Costs - United States, 1995-1999. Morbidity and Mortality Weekly Report [serial online]. 2002;51:300-303 [cited 2006 May 23]. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5114a2.htm. Accessed September 2007.
4. Centers for Disease Control and Prevention. Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses - United States, 1997-2001. Morbidity and Mortality Weekly Report [serial online]. 2005;54:625-628 [cited 2006 May 23]. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5425a1.htm. Accessed September 2007.
5. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. [cited 2006 May 23]. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2000. Available at: http://www.surgeongeneral.gov/tobacco/default.htm. Accessed September 2007.
6. Kleber HD, Weiss RD, Anton RF, et al. Practice Guidelines for the Treatment of Patients with Substance Use Disorders. 2nd ed. American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders, Compendium 2006. Arlington, Va: American Psychiatric Association; 2006:291-563.
7. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12:21-27.
8. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004; CD000146.
9. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992;44:498-529
10. Hughes FR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol. 1993;61:751-760.
11. Hughes JR, Novy P, Hatsukami DK, Jensn J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. Alcohol Clin Exp Res. 2003;27:946-954.
12. Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15:453-467.
13. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267-1276.
14. Garvey AJ, Kinnunen T, Nordstrom BL, et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res. 2000;2:53-63.
15. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003;5:635-644.
16. Lee EW, D'Alonzo GE. Cigarette smoking, nicotine addiction, and its pharmacologic treatment. Arch Intern Med. 1993;153:34-48.
17. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597-613.
18. Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990;264:1560-1564.
19. Hughes JR. Risk-benefit assessment of nicotine preparations in smoking cessation. Drug Saf. 1993;8:49-56.
20. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40:661-684.
21. Fiore M, United States Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service; 2000.
22. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324-329.
23. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation: a randomized placebo-controlled, double-blind study. Arch Intern Med. 1994;154:2567-2572.
24. Schneider NG, Olmstead RE, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 2005;90:1671-1682.
25. Rose JE, Behm F. Refined cigarette smoke as a method for reducing nicotine intake. Pharmacol Biochem Behav. 1987;28:305-310.
26. Tonneson P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269:1268-1271.
27. Leishow SJ. Nicotine vaporizer: review of results. In: Future Directions in Nicotine Replacement Therapy. Chester, UK: Adis, 1994;99-103.
28. Sutherland G, Russell MA, Stapleton J, Feyerabend C, Ferno O. Nasal nicotine spray: a rapid nicotine delivery system. Psychoparmacology (Berl). 1992;105:512-518.
29. West R, Hajek P, Foulds J, Nisson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychoparmacology (Berl). 2000;149:198-202.
30. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000;149:198-202.
31. Perkins KA, Grobe JE, Caggiula A, Wilson AS, Stiller RL. Acute reinforcing effects of low-dose nicotine nasal spray in humans. 1997;56:235-241.
32. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ. 2000;5:355-358.
33. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation a meta-analysis. Tob Control. 2006;15:280-285.
34. Glassman, A.H. Cigarette smoking and its comorbidity. (NIDA Research Monograph No. 172). Washington, DC: U.S. Government Printing Office; 1997; 52-60.
35. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999;288:88-92.
36. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. Oct 2000;295:321-327.
37. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
38. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;CD000031.
39. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998;158:2035-2039.
40. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55:683-690.
41. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science. 1984;226:864-866.
42. Ornish SA, Zisook S, McAdams LA. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Arch Intern Med. 1988;148:2027-2031.
43. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2000:CD000058.
44. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403-1407.
45. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53:136-143.
46. Gonzales D, Rennard SI, Nides M, et al, for the Varenicline Phase 3 Study Group. Varenicline, an ·4·2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized control trial. JAMA. 2006;296:47-55.
47. Jorenby DE, Hays JT, Rigotti NA, et a, for the Varenicline Phase 3 Study Group. Efficacy of varenicline and a4a2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained release bupropion and placebo for smoking cessation. A randomized control trial. JAMA. 2006;296:56-63.
48. Hatsukami DK, Rnnared S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456-467.
49. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35:2031-2040.
50. Bunce CJ, Loudon PT, Akers C, et al. Development of vaccines to help treat drug dependence. Curr Opin Mol Ther. 2003;5:58-63.
51. Heading CE. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr Opin Investig Drugs. 2007;8:71-77.
52. Kosten TR, O'Connor PG. Current concepts - management of drug withdrawal. N Engl J Med. 2003;348:1786-1795.
53. Ciraulo DA, Shader RI. Clinical Manual of Chemical Dependence. Washington, DC: American Psychiatric Press; 1991.
54. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278:144-151.
55. Ntais C, Pakos E, Kyzas P, Ioonidis J. Benzodiazapines for alcohol withdrawal. Cochrane Database Syst Rev. 2005;CD005063.
56. Bjorkquist, SE, Isohanni M, Makela R, et al. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre, double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333-342.
57. Agricola, R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: A double-blind comparison with tiapride. J Int Med Res. 1982;10:160-165.
58. Malcolm R, Ballenger JC, Sturgis ET, Anton, R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146:617-621.
59. Malcolm R, Myrick H, Brady KT, and Ballenger, JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Add. 2001;10(suppl):16-23.
60. Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med. 1990;88:647-655.
61. Jung YC, Namkoong K. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J. 2006;47:167-178.
62. Philippi E, Patel A, Shenouda N, Tallis G, eds. Physicians Desk Reference, Issue 2. Montvale, NJ: Thomson; 2007:215.
63. Fuller RF, Roth HP. Disulfiram for the treatment of alcoholism: An evaluation in 128 men. Ann Intern Med. 1979;90:901-904.
64. Fuller, RF, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: A Veteran's Administration cooperative study. JAMA. 1986;256:1449-1455.
65. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281:1318-1325.
66. Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, Rounsaville B. VA VISN I MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27:160-165.
67. Besson J, Aeby F, Kasas A, Lehert P, Potgeiter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-279.
68. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
69. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
70. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20:427-435.
71. Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. Psychopharmacol. 2001;21:72-77.
72. Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25:349-357.
73. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27:1142-1149.
74. Morely KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-1462.
75. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
76. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgeiter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
77. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135-141.
78. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
79. Johnson B, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet. 2003;361:1677-1685.
80. Kranzler HR, Burleson JA, DelBoca FK, et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry. 1994;51:720-731.
81. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2007. In press.
82. Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996;11:109-117.
83. Tiihonen J, Ryynanen OP, Kauhanen J, Hakola HP, Salaspuro M. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry. Jan 1996;29:27-29.
84. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction. 1995;90:87-99.
85. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
86. Balldin J, Berggren U, Engel J, Eriksson M, Hard E, Soderpalm B. Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res. 1994;18:1133-1136.
87. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261-265.
88. Bremner KE, Lanctot KL. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992;51:729-739.
89. Naranjo CA, Poulos CX, Naranjo CA, Sellers EM. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol. 1989;7:255-266.
90. Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000;60:161-168.
91. Malcolm R, Moore JW, Kajdasz DK, Cochrane CE. Pergolide meylate. Adverse events occuing in the treatment of cocaine dependence. Am J Addict. 1997;6:117-123.
92. Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998;93:713-727.
93. George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000;47:1080-1086.
94. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch Gen Psychiatry. 2004;61:264-272.
95. Petrakis IL, Carroll KM, Nich C et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95:219-228.
96. Nich C, McCance-Katz EF, Petrakis IL, Cubells JF, Rounsaville BJ, Carroll KM. Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addict Behav. 2004;29:1123-1128.
97. Ebadi M, Sharma S, Shavali S, et al. Neuroprotective actions of selegiline. J Neurosci Res. 2002;67:285-289.
98. Haberny KA, Walsk SL, Ginn DH, et al. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. 1995;39:55-62.
99. Bartzokis G, Beckson M, Newton T, et al. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology. 1999;20:582-590.
100. Gawin FH, Ellinwood EH. Cocaine and other stimulants: actions, abuse and treatment. N Engl J Med 1998;318:1173-1182.
101. Levin FR, Lehman AF. Meta-analysis of desipramine an adjunct in the treatment of cocaine addiction. J Clin Pharmacol. 1991;11:374-378.
102. Lima MS, Reisser AA, Soares BG, et al. Antidepressants for cocaine dependence. Cochrane Database Syst Rev. 2001;CD002950.
103. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995;40:125-131.
104. Nunes EV, Quitkin FM, Brady R, et al. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry. 1991;148:667-669.
105. Ziedonis DM, Kosten TR. Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull. 1991;27:337-343.
106. Kosten TR, Gawin FH, Silverman DG, et al. Intravenous cocaine challenges during desipramine maintenance. Neuropsychopharmacology. 1992;7:169-176.
107. Oliveto AH, Feingold A, Schottenfeld R, et al. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999;56:812-820.
108. Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol. 1995;15:163-174.
109. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64:1440-1448.
110. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine (benzoylecgonine) free urines in recently admitted cocaine-dependent methadone treated patients: preliminary results of a randomized clinical trial. Addiction. 2003;98:1625-1632.
111. Gonzalez G, Desai R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007;87:1-9.
112. Kampman KM, Pettinati H, Linch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75:233-240.
113. Brodie JD, Figueroa E, Laska EM, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122-125.
114. Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995;38:221-227.
115. Montoya ID, Levin FR, Fudala PJ, et al. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend. 1995;38:213-219.
116. Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry. 1989;26:637-639.
117. Kosten TR, Schottenfeld RS, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-364.
118. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-720.
119. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340-349.
120. Alterman AL, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 1992;31:19-29.
121. Kampman KM, Volpicelli JR, Alterman A, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 1996;41:25-33.
122. Kampman KM, Volpicelli JR, Alterman AI, et al. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry. 2000;157:2052-2054.
123. Shoptaw S, Kintaudi PC, Charuvastra C, et al. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend. 2002;66:217-224
124. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;130:205-211.
125. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67:554-566.
126. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30:205-211.
127. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl). 2003;165:260-269.
128. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1061-1040.
129. Kosten TR, Rosen, M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002;20:1196-1204.
130. Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology. 2000;148:251-262.
131. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine, pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005;58:158-164.
132. Martell BA. Cocaine vaccines [abstract] College on problems of drug dependence. 69th Annual Scientific Meeting; 2007 Jun 16-21;Quebec City, CA
133. World Health Organization (WHO). Neuroscience of psychoactive use and dependence. Geneva; WHO, 2004.
134. Payte JT. Methadone maintenance treatment: the first thirty years. J Psychoactive Drugs. 1997;29:149-153.
135. Join Together. Congress raises buprenorphine treatment cap to 100 2006 Dec 11. Available at: http://www.jointogether.org/news/headlines/inthenews/2006/ congress-raises.html. Accessed December 20, 2006.
136. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl). 2002;161:202-212.
137. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction, a clinical trial with methadone hydrochloride. JAMA. 1965;193:646-650.
138. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485-488.
139. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatmentof opioid dependence. Ann Intern Med. 1993;119:23-27.
140. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend. 1993;33:105-117.
141. Ling W, Charuvastra C, Kaim SC, Klett CJ. Mehtadyl acetate and methadone as maintenance treatments for heroin addictis: a Veterans Administration cooperative study. Arch Gen Psychiatry. 1976;33:709-720.
142. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate versus high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000-1005.
143. Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit. 2001;23:553-555.
144. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001;33:1595-1597.
145. Senay, EC, Dorus W, Goldberg F, Thornton W. Withdrawal from methadone maintenance: Rate of withdrawal and expectation. Arch Gen Psychiatry. 1977;34:361-367.
146. Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10:249-266
147. Johnson RE, Jaffe, JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
148. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study [letter]. Neuropsychopharmacology. 1998;18:403-404.
149. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 suppl):S13-27.
150. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003;212S: S29-S37.
151. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
152. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 suppl):S59-77.
153. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry. 1973;28:784-791.
154. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther. 1996;279:524-538.
155. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther. 1981;216:45-54.
156. Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997;14:529-534.
157. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2003;CD001333.
158. Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry. 1999;56:493-502.
159. Carroll KM. Relapse prevention as a psychosocial treatment approach: a review of controlled clinical trials. Exp Clin Psychopharmacol. 1996;4:46-54.
160. Carroll KM. Manual-guided psychosocial treatment: a new virtual requirement for pharmacotherapy trials? Arch Gen Psychiatry. 1997;54:923-928.
161. Higgins ST, Budney AJ, Bickel WK. Applying behavioral concepts and principles to the treatment of cocaine dependence. Drug Alcohol Depend. 1994;34:87-97.
162. Higgins ST, Badger GJ, Budney AJ. Initial abstinence and success in achieving longer term cocaine abstinence. Exp Clin Psychopharmacol. 2000;8:377-386.
163. Higgins ST, Wong CJ, Badger GJ, et al. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol. 2000;68:64-72.
164. Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry. 1996;53:409-415.
165. Petry NM, Peirce JM, Stitzer ML, et al. Effect of prize-based incentives on outcomes in stimulant abusers in outpaient psychosocial treatment programs. Arch Gen Psychiatry. 2005;62:1148-1156.
166. Weinstock J, Alessi SM, Petry NM. Regardless of psychiatric severity the addition of contingency management to standard treatment improves retention and drug use outcomes. Drug Alcohol Depend. 2007;87:288-296.
167. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340-349.
168. Olmstead TA, Sindelar JL, Petry NM. Cost-effectveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend. 2007;87:175-182.
169. Grassi MC, Cioce AM, Giudici FD, Antonilli L, Nencini P. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacol Res. 2007;55:117-121.
170. Rawson RA, McCann MJ, Fammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101:267-274.